Grifols announces a next-generation automated system to enhance efficiency and flexibility in transfusion medicine laboratories

Barcelona, Spain, June 22, 2026 – Grifols (MCE:GRF, MCE:GRF. P, NASDAQ:GRFS), a global healthcare company and leader in plasma-derived medicines and innovative diagnostic solutions, today announced the launch of Evanzys IH, a next-generation automated system designed to enhance laboratory efficiency and flexibility in the analysis of immunohematology samples. The announcement was made during the opening of the International Society of Blood Transfusion (ISBT) Congress, which is being held in Kuala Lumpur (Malaysia) through June 24.

Evanzys IH is an innovative, modular, fully automated, track-enabled system developed to optimize laboratory operations, reduce manual intervention and support healthcare professionals in delivering safer and faster transfusion results. With this launch, Grifols further strengthens its existing immunohematology portfolio, including Erytra and Erytra Eflexis, while responding to laboratories’ growing demand for scalable, connected and future-ready workflows.

“Evanzys IH represents a major milestone in our commitment to advancing innovation in transfusion medicine. With this new modular, track-enabled solution - the most innovative platform in the field - we are empowering laboratories to meet increasing automation demands while upholding the highest standards of quality, safety and efficiency”, said Antonio Martínez, president of Grifols Diagnostic.

The launch of Evanzys IH, which expands Grifols’ portfolio of blood typing solutions, is yet another example of the company’s investment in R&D to develop cutting-edge diagnostic technologies. These innovations support the analysis of millions of donor and patient samples each year and reinforce Grifols’ position as a global leader in blood screening and typing solutions.

In addition to this launch, the company is showcasing its latest innovations in immunohematology and donor screening at ISBT 2026, including Total Lab Automation (TLA) capabilities, advanced automation and digital connectivity. As part of the EVANZCare experience, customers benefit from a broader ecosystem of services, resources and expertise designed to strengthen long-term partnerships and support laboratory success. This approach reflects Grifols’ commitment to delivering value beyond products alone. These integrated solutions represent a significant step toward the future of transfusion medicine by enabling end-to-end workflow automation—from sample handling to results management—with full traceability and real-time performance insights.